AstraZeneca PLC (AZN)vsPhibro Animal Health Corporation (PAHC)
AZN
AstraZeneca PLC
$172.48
+0.48%
HEALTHCARE · Cap: $261.94B
PAHC
Phibro Animal Health Corporation
$36.95
+1.59%
HEALTHCARE · Cap: $1.34B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3929% more annual revenue ($60.44B vs $1.50B). AZN leads profitability with a 17.2% profit margin vs 6.3%. AZN appears more attractively valued with a PEG of 1.33. PAHC earns a higher WallStSmart Score of 65/100 (C+).
AZN
Buy64
out of 100
Grade: C+
PAHC
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$172.48
$21.48 discount
Margin of Safety
-11.4%
Fair Value
$46.24
Current Price
$36.95
$9.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Smaller company, higher risk/reward
6.3% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : PAHC
The strongest argument for PAHC centers on Return on Equity, P/E Ratio. Revenue growth of 10.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : PAHC
The primary concerns for PAHC are PEG Ratio, Market Cap, Profit Margin. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while PAHC is a value play — different risk/reward profiles.
PAHC carries more volatility with a beta of 0.46 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
PAHC scores higher overall (65/100 vs 64/100) and 10.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Phibro Animal Health Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?